Genetic variants and associations of 25-hydroxyvitamin D concentrations with major clinical outcomes

JAMA

Volumn 308, Issue 18, 2012, Pages 1898-1905

  Levin, Gregory P ^a   Robinson Cohen, Cassianne ^a   De Boer, Ian H ^a,b   Houston, Denise K ^c   Lohman, Kurt ^c,d   Liu, Yongmei ^c   Kritchevsky, Stephen B ^c   Cauley, Jane A ^e   Tanaka, Toshiko ^f   Ferrucci, Luigi ^f   Bandinelli, Stefania ^g   Patel, Kushang V ^a   Hagström, Emil ^h   Michaëlsson, Karl ^h   Melhus, Håkan ^h   Wang, Thomas ⁱ   Wolf, Myles ^j   Psaty, Bruce M ^a,b   Siscovick, David ^b   Kestenbaum, Bryan ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

^d WAKE FOREST UNIVERSITY   (United States)

^e UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^f NATIONAL INSTITUTE ON AGING   (United States)

^g SANTA MARIA ANNUNZIATA HOSPITAL   (Italy)

^h UPPSALA UNIVERSITY   (Sweden)

ⁱ HARVARD MEDICAL SCHOOL   (United States)

^j UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; CUBILIN; MEGALIN; VITAMIN D BINDING PROTEIN; VITAMIN D RECEPTOR;

AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CUBILIN GENE; CYP24A1 GENE; CYP27B1 GENE; FEMALE; GENE; GENE FUNCTION; GENE INTERACTION; GENETIC DIFFERENCE; GENETIC RISK; GENETIC VARIABILITY; HEART INFARCTION; HIP FRACTURE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEGALIN GENE; MORTALITY; NEOPLASM; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; VITAMIN BLOOD LEVEL; VITAMIN D BINDING PROTEIN GENE; VITAMIN D RECEPTOR GENE;

EID: 84868658828     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2012.17304     Document Type: Article

References (46)

1. Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357(3):266-281.
2. Rosen CJ. Clinical practice: vitamin D insufficiency. N Engl J Med. 2011;364(3):248-254.
3. Giovannucci E, Liu Y, Hollis BW, Rimm EB. 25-Hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. Arch Intern Med. 2008; 168(11):1174-1180.
4. Melamed ML, Michos ED, Post W, Astor B. 25-Hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med. 2008;168(15):1629-1637.
5. Dobnig H, Pilz S, Scharnagl H, et al. Independent association of low serum 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D levelswith all-cause and cardiovascular mortality. Arch Intern Med. 2008;168(12):1340-1349.
6. Wang TJ, Pencina MJ, Booth SL, et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation. 2008;117(4):503-511.
7. Looker AC, Mussolino ME. Serum 25-hydroxyvitaminDand hip fracture risk in olderUS white adults. J Bone Miner Res. 2008;23(1):143-150.
8. de Boer IH, Kestenbaum B, Shoben AB, Michos ED, Sarnak MJ, Siscovick DS. 25-Hydroxyvitamin D levels inversely associate with risk for developing coronary artery calcification. J Am Soc Nephrol. 2009;20(8):1805-1812.
9. Cauley JA, Lacroix AZ, Wu L, et al. Serum 25-hydroxyvitamin D concentrations and risk for hip fractures. Ann Intern Med. 2008;149(4):242-250.
10. de Boer IH, Levin GP, Robinson-Cohen C, et al. Serum 25-hydroxyvitamin D concentration and risk for major clinical disease events in a communitybased population of older adults: a cohort study. Ann Intern Med. 2012;156(9):627-634.
11. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest. 2002;110(2):229-238.
12. van Etten E, Mathieu C. Immunoregulation by 1,25-dihydroxyvitamin D3: basic concepts. J Steroid Biochem Mol Biol. 2005;97(1-2):93-101.
13. Xiang W, Kong J, Chen S, et al. Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systems. Am J Physiol Endocrinol Metab. 2005;288(1):E125-E132.
14. Manson JE, Bassuk SS, Lee IM, et al. The VITamin D and OmegA-3 TriaL (VITAL): rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease. Contemp Clin Trials. 2012;33(1):159-171.
15. Fried LP, Borhani NO, Enright P, et al. The Cardiovascular Health Study: design and rationale. Ann Epidemiol. 1991;1(3):263-276.
16. Kestenbaum B, Katz R, de Boer I, et al. Vitamin D, parathyroid hormone, and cardiovascular events among older adults. J Am Coll Cardiol. 2011;58 (14):1433-1441.
17. Simonsick EM, Newman AB, Nevitt MC, et al; Health ABC Study Group. Measuring higher level physical function in well-functioning older adults: expanding familiar approaches in the Health ABC study. J Gerontol A Biol Sci Med Sci. 2001;56(10):M644-M649.
18. Ferrucci L, Bandinelli S, Benvenuti E, et al. Subsystems contributing to the decline in ability to walk: bridging the gap between epidemiology and geriatric practice in the InCHIANTI study. J Am Geriatr Soc. 2000;48(12):1618-1625.
19. Melhus H, Snellman G, Gedeborg R, et al. Plasma 25-hydroxyvitamin D levels and fracture risk in a community-based cohort of elderly men in Sweden. J Clin Endocrinol Metab. 2010;95(6):2637-2645.
20. Hollis BW. Measuring 25-hydroxyvitamin D in a clinical environment: challenges and needs. Am J Clin Nutr. 2008;88(2):507S-510S.
21. Robinson-Cohen C, Katz R, Hoofnagle AN, et al. Mineral metabolism markers and the long-term risk of hip fracture: the Cardiovascular Health Study. J Clin Endocrinol Metab. 2011;96(7):2186-2193.
22. Jorde R, Sneve M, Hutchinson M, Emaus N, Figenschau Y, Grimnes G. Tracking of serum 25-hydroxyvitamin D levels during 14 years in a population-based study and during 12 months in an intervention study. Am J Epidemiol. 2010;171(8):903-908.
23. Sherman SS, Hollis BW, Tobin JD. Vitamin D status and related parameters in a healthy population: the effects of age, sex, and season. J Clin Endocrinol Metab. 1990;71(2):405-413.
24. Bolland MJ, Grey AB, Ames RW, et al. The effects of seasonal variation of 25-hydroxyvitamin D and fat mass on a diagnosis of vitamin D sufficiency. Am J Clin Nutr. 2007;86(4):959-964.
25. Shoben AB, Kestenbaum B, Levin G, et al. Seasonal variation in 25-hydroxyvitamin D concentrations in the Cardiovascular Health Study. Am J Epidemiol. 2011;174(12):1363-1372.
26. Wang Y, Jacobs EJ, McCullough ML, et al. Comparing methods for accounting for seasonal variability in a biomarker when only a single sample is available: insights from simulations based on serum 25-hydroxyvitamin D. Am J Epidemiol. 2009;170(1):88-94.
27. Psaty BM, O'Donnell CJ, Gudnason V, et al; CHARGE Consortium. Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium: design of prospective meta-analyses of genome-wide association studies from 5 cohorts. Circ Cardiovasc Genet. 2009;2(1):73-80.
28. Ives DG, Fitzpatrick AL, Bild DE, et al. Surveillance and ascertainment of cardiovascular events: the Cardiovascular Health Study. Ann Epidemiol. 1995;5(4):278-285.
29. Eilers PH, Marx BD. Flexible smoothing with Bsplines and penalties. Stat Sci. 1996;11:89-121.
30. Benjamini Y, Hochberg B. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B. 1995;57:289-300.
31. Benjamini Y, Yekutieli D. Quantitative trait Loci analysis using the false discovery rate. Genetics. 2005;171(2):783-790.
32. Smith NL, Rice KM, Lumley T, Heckbert SR, Psaty BM. Discovering novel risk factors for venous thrombosis: a candidate-gene approach. Thromb Res. 2009;123(suppl 4):S25-S29.
33. Xiao R, Boehnke M. Quantifying and correcting for the winner's curse in genetic association studies. Genet Epidemiol. 2009;33(5):453-462.
34. Woolf B.On estimating the relation between blood group and disease. Ann Hum Genet. 1955;19(4):251-253.
35. Johnson AD, Handsaker RE, Pulit SL, Nizzari MM, O'Donnell CJ, de Bakker PI. SNAP: a web-based tool for identification and annotation of proxy SNPs using HapMap. Bioinformatics. 2008;24(24):2938-2939.
36. Liu CK, Chen YH, Tang CY, et al. Functional analysis of novel SNPs and mutations in human and mouse genomes. BMC Bioinformatics. 2008;9(suppl 12):S10.
37. Morrison NA, George PM, Vaughan T, Tilyard MW, Frampton CM, Gilchrist NL. Vitamin D receptor genotypes influence the success of calcitriol therapy for recurrent vertebral fracture in osteoporosis. Pharmacogenet Genomics. 2005;15(2):127-135.
38. Penna-Martinez M, Ramos-Lopez E, Stern J, et al. Vitamin D receptor polymorphisms in differentiated thyroid carcinoma. Thyroid. 2009;19(6):623-628.
39. Onen IH, Ekmekci A, ErogluM, Konac E, Yesil S, Biri H. Association of genetic polymorphisms in vitaminDreceptor gene and susceptibility to sporadic prostate cancer. Exp Biol Med (Maywood). 2008;233(12):1608-1614.
40. Lurie G, Wilkens LR, Thompson PJ, et al. Vitamin D receptor gene polymorphisms and epithelial ovarian cancer risk. Cancer Epidemiol Biomarkers Prev. 2007;16(12):2566-2571.
41. Raimondi S, Johansson H, Maisonneuve P, Gandini S. Review and meta-analysis on vitamin D receptor polymorphisms and cancer risk. Carcinogenesis. 2009;30(7):1170-1180.
42. Gong G, Stern HS, Cheng SC, et al. The association of bone mineral density with vitamin D receptor gene polymorphisms. Osteoporos Int. 1999;9(1):55-64.
43. Thakkinstian A, D'Este C, Eisman J, Nguyen T, Attia J. Meta-analysis of molecular association studies: vitamin D receptor gene polymorphisms and BMD as a case study. J Bone Miner Res. 2004;19(3):419-428.
44. Ji GR, Yao M, Sun CY, Li ZH, Han Z. BsmI, TaqI, ApaI and FokI polymorphisms in the vitamin D receptor (VDR) gene and risk of fracture in Caucasians: a meta-analysis. Bone. 2010;47(3):681-686.
45. Karami S, Brennan P, Rosenberg PS, et al. Analysis of SNPs and haplotypes in vitamin D pathway genes and renal cancer risk. PLoS One. 2009;4(9):e7013.
46. Cheskis B, Freedman LP. Ligand modulates the conversion of DNA-bound vitamin D3 receptor (VDR) homodimers into VDR-retinoid X receptor heterodimers. Mol Cell Biol. 1994;14(5):3329-3338.